The Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Abstracts:
Saturday, November 9
11:50 am - 12:20 pm
Location: Potomac Ballroom

**IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1-selected NSCLC**
Author: Roy S. Herbst

Friday, November 8
7:00 am - 8:00 pm
Location: Prince George's Exhibition Halls AB

**DNA damage response (DDR) is associated with increased adaptive anti-tumor responses and PD-L1 expression in human non-small cell lung cancer.**
Authors: Shruti Desai, Aravind N. Kalathil, Roy S. Herbst, Ranjit S. Bindra, Patricia LoRusso, Kurt Schalper

Saturday, November 9
7:00 am - 8:30 pm
Location: Prince George's Exhibition Halls AB

**Differential immune contexture of human colorectal carcinomas with mismatch repair deficiency (MSI-H) and increased DNA damage responses (DDR).**
Authors: Shruti Desai, Aravind N. Kalathil, Ila Datar, Charles Fuchs, Patricia LoRusso, Ranjit S. Bindra, Kurt Schalper

**Discovery of biomarkers associated with benefit from PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling**
Authors: Jon Zugazagoitia, Scott Gettinger, Roy S. Herbst, Kurt Schalper, David Rimm
Quantitative/spatial analysis of Tregs reveal a prominent biomarker role in human non-small cell lung cancer (NSCLC)
Authors: Richa Gupta, Shruti Desai, Roy S. Herbst, David Rimm, Sarah Goldberg, Kurt Schalper

Myeloid cell contexture and IL-8 expression as a candidate immunotherapy target in Non-Small Cell Lung Cancer (NSCLC).
Authors: Venkata Vamsi Nagineni, Kurt Schalper, Shruti Desai, Miguel F. Sanmamed, Roy S. Herbst, Venkata Vamsi Nagineni

Expression and clinical significance of the CD47/SIRPα pathway as a candidate immunotherapy target in non-small cell lung cancer (NSCLC)
Authors: Shruti Desai, Franz Villarroel-Espindola, Patricia Gaule, Kurt Schalper

Long survival associated with receipt of anti-CTLA-4 in patients with metastatic melanoma from acral lentiginous, mucosal and uveal primary tumors
Authors: Nicholas Klemen, Melinda Wang, Kelly Olino, James Clune, Stephan Ariyan, Charles Cha, Sarah Weiss, Harriet Kluger, Mario Sznol

A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults with Head and Neck Cancer
Author: Barbara Burtness

**Oral Abstracts:**

**Saturday, November 9**

Concurrent Rapid Oral Abstract Presentations - Basic
12:50 pm – 1:50 pm
Location: National Harbor 10-11
Co-Chairs: Aaron Ring and Jessica E. Thaxton

**Sessions:**

**Friday, November 8**

Session 201: Richard V. Smalley, MD Memorial Lectureship
8:35 am - 9:25 am
Location: Potomac Ballroom
Chair/Introduction: Mario Sznol

Concurrent Session 206: High Impact Clinical Trials  
4:50 pm - 6:15 pm  
Location: Prince George’s Exhibition Hall C  
Co-Chairs: Roy S. Herbst (Introduction) and Jeffrey Weber

Saturday, November 9

Point-Counterpoint: New Data and Controversies on Immunotherapy Combinations in the First-Line Treatment of NSCLC  
7:00 am - 7:45 am  
Location: Cherry Blossom Ballroom

    7:20 am – 7:30 am  
    IO-chemotherapy Combinations  
    Speaker: Roy Herbst

    7:30 am – 7:45 am  
    Panel Discussion  
    Moderators: Mario Sznol and Jedd D. Wolchok  
    Panelists: Roy Herbst, Naiyer A. Rizvi, Julie Brahmer

Session 302: Keynote Address  
8:55 am - 9:45 am  
Location: Potomac Ballroom  
Chair/Introduction: Mario Sznol

Session 306: Presidential Session  
2:05 pm - 3:30 pm  
Location: Potomac Ballroom  
Chair/Introduction: Mario Sznol

Concurrent Session 307: Machine Learning Approaches and Applications  
3:45pm - 5:00 pm  
Location: Cherry Blossom Ballroom  
Co-Chairs: Kurt A. Schalper and Douglas Lauffenburger

3:45 pm  
Clinicopathologic and Molecular Markers to Assess Anti-tumor Immune Responses
Speaker: Kurt A. Schalper

**4:00 pm**
*Deciphering Cell-Cell Interactions in the Melanoma TME from Single-cell Profiling Data*
Speaker: Kathryn Miller-Jensen

**Concurrent Session 308: Clinical Management**
**3:45 pm - 5:00 pm**
**Location:** National Harbor 10-11
**Co-Chairs:** Marianne Davies and Elad Sharon

**Concurrent Session 311: A Tale of Two Brain Tumors: Primary versus Metastatic CNS Tumors**
**5:15 pm - 6:30 pm**
**Location:** National Harbor 10-11

**5:35 – 5:55 pm**
*Immunobiology of CNS Metastatic Tumors*
Speaker: Harriet Kluger

**Sunday, November 10**

**8:00 am**
**Location:** Prince George's Exhibition Hall C
*Organizer Welcome*
Speaker: Marianne Davies